Claims
- 1. A method for the treatment of Type II diabetes in a human or non-human mammal which comprises administering an effective, non-toxic, amount of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.
- 2. The method of treatment according to claim 1 which comprises administration to said human or non-human mammal in need thereof from one to six times per day.
- 3. The method of treatment according to claim 1 which comprises administration to said human or non-human mammal in need thereof one or two times per day.
- 4. The method of treatment according to claim 1 which comprises administration of a composition comprising 0.1 to 250 mg of an effective, non-toxic, amount of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.
- 5. A pharmaceutical composition comprising 0.1 to 250 mg of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
- 6. The pharmaceutical composition of claim 5 in the form of a unit dosage.
- 7. A process for preparing a pharmaceutical composition comprising a non-toxic amount in the range of 0.1 to 250 mg of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor, which process comprises admixing 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and the pharmaceutically acceptable carrier therefor.
- 8. The process according to claim 7 wherein the composition is in unit dosage form and comprises 0.1 to 250 mg of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof.
- 9. The method of treatment according to claim 1 which comprises administration to said human or non-human mammal in need thereof six times per day.
- 10. The pharmaceutical composition of claim 6 in the form of 6 unit dosages.
Priority Claims (3)
Number |
Date |
Country |
Kind |
8720825 |
Sep 1987 |
GB |
|
8727987 |
Nov 1987 |
GB |
|
8802454 |
Feb 1988 |
GB |
|
Parent Case Info
This application is a Continuation of application Ser. No. 08/053,997, filed Apr. 26, 1993, now abandoned, which in turn is a Continuation-in-part of U.S. application Ser. No. 07/641,474, filed Jan. 15, 1991, now U.S. Pat. No. 5,232,925 which in turn is a Continuation-In-Part of U.S. application Ser. No. 07/457,272, filed Dec. 27, 1989, now U.S. Pat. No. 5,002,953, which in turn is a Continuation-In-Part of U.S. application Ser. No. 07/238,764, filed Aug. 30, 1988, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5478852 |
Olefsky |
Dec 1995 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/053997 |
Apr 1993 |
US |
Child |
08/358327 |
|
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
07/641474 |
Jan 1991 |
US |
Child |
08/053997 |
|
US |
Parent |
07/457272 |
Dec 1989 |
US |
Child |
07/641474 |
|
US |
Parent |
07/238764 |
Aug 1988 |
US |
Child |
07/457272 |
|
US |